Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Recruiting

Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Sponsor:

AstraZeneca

Code:

NCT05775159

Conditions

Hepatocellular Carcinoma

Biliary Tract Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Volrustomig

Bevacizumab

Lenvatinib

Rilvegostomig

Gemcitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-10. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-05-30.